Phase 3b open-label study of elexacaftor/tezacaftor/ivacaftor on glucose tolerance in cystic fibrosis with abnormal glucose metabolism

Phase 3, open-label, single-arm trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Change from baseline in 2-hour blood glucose following oral glucose tolerance test. Started Oct 2020; status: completed.